3-Hydroxyanagrelide | 733043-41-9

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-Hydroxyanagrelide
• 英文别名: 6,7-dichloro-3-hydroxy-1,5-dihydro-imidazo[2, 1-b ]quinazolin-2-one；3-Hydroxy Anagrelide；6,7-dichloro-3-hydroxy-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
• CAS: 733043-41-9
• 化学式: C₁₀H₇Cl₂N₃O₂
• 分子量: 272.09
• InChiKey: KAXTUTDKZVOONF-UHFFFAOYSA-N

物化性质

• 熔点：
  270-275°C
• 沸点：
  435.4±55.0 °C(Predicted)
• 密度：
  1.92±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMF（轻微）、DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-5,6-二氯-3,4-二氢喹唑啉氢溴酸盐 在 sodium periodate 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 丙酮 、 mineral oil 为溶剂， 反应 62.5h， 生成 3-Hydroxyanagrelide
  参考文献：
  名称：

  SYNTHESIS AND STABILITY OF 3-HYDROXYANAGRELIDE, A BIOLOGICALLY POTENT METABOLITE OF ANAGRELIDE

  摘要：

  Metabolism of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (anagrelide), a drug for treating essential thrombocythemia, gives 6,7-dichloro-3-hydroxy-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (3-hydroxyanagrelide) and 2-amino-5,6-dichloro-3,4-dihydroquinazoline. To enable the properties of 3-hydroxyanagrelide to be fully evaluated, the racemic compound has been synthesized. In pH 7.4 aqueous buffer 3-hydroxyanagrelide readily equilibrates with an isomer, 6,7-dichloro-1-hydroxy-3,5-dihydroimidazo[1,2-alpha]-quinazolin-2-one,and is also hydrolyzed to 2-amino-5,6-dichloro-3,4-dihydroquinazoline. 3-Hydroxyanagrelide (half-life 40 hours) was the dominant species at equilibrium and it was concluded that the equilibration and decomposition are sufficiently slow that published assays of 3-hydroxyanagrelide are reliable.

  DOI：

  10.3987/com-12-s(n)115

文献信息

• Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
  申请人：Franklin Richard

  公开号：US20060030574A1

  公开（公告）日：2006-02-09

  In accordance with the present invention there is provided a method for the treatment of peripheral arterial diseases in a host comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or analogues thereof.

  根据本发明，提供了一种治疗宿主外周动脉疾病的方法，包括向宿主投与式(I)到式(III)或其类似物的治疗有效量的化合物。
• Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
  申请人：Glidden Paul F.

  公开号：US20090324710A1

  公开（公告）日：2009-12-31

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，用于通过给予药剂，包括anagrelide和anagrelide衍生物，将循环血小板数量降至低于正常水平或低于正常水平，以抑制血管闭塞事件，包括栓塞。提供了包含这些药剂的方法和制药制剂。
• CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR
  申请人：Glidden Paul F.

  公开号：US20130022671A1

  公开（公告）日：2013-01-24

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，以抑制血管闭塞事件，包括栓塞，通过给予药物，包括阿格列酯和阿格列酯衍生物，将循环血小板数量降低到低于正常水平或低于正常水平的水平。提供了包含这些药物的方法和制药制剂。
• Quinazoline derivatives and their use in the treatment of thrombocythemia
  申请人：Franklin Richard

  公开号：US20060052601A1

  公开（公告）日：2006-03-09

  A method for the treatment of thrombocythemia in a subject comprising administering a therapeutically effective amount of compounds having the formulas (I) through (III) or equilibrating forms thereof.

  一种治疗受试者血小板增多症的方法，包括施用治疗有效量的具有式 (I) 至 (III) 的化合物或其平衡形式。
• [EN] QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA<br/>[FR] DERIVES DE QUINAZOLINE, UTILISATION DE CES DERNIERS DANS LE TRAITEMENT DE LA THROMBOCYTHEMIE
  申请人：SHIRE HOLDINGS AG

  公开号：WO2006017822A3

  公开（公告）日：2006-08-24